Literature DB >> 17403919

Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid.

Francesca Fiore1, Barbara Castella, Barbara Nuschak, Raffaello Bertieri, Sara Mariani, Benedetto Bruno, Francesca Pantaleoni, Myriam Foglietta, Mario Boccadoro, Massimo Massaia.   

Abstract

Vgamma9/Vdelta2 (gammadelta) T cells play a major role in innate immunity against microbes, stressed, and tumor cells. They represent less than 5% of peripheral blood lymphocytes but can be activated and expanded in vitro by aminobisphosphonates (ABP)-treated monocytes. The aim of this work was to determine whether ABP-treated dendritic cells (DCs) can also activate gammadelta T cells and regulate immune responses mediated by conventional alphabeta T cells. Highly purified immature (iDC) and mature DC (mDC) were generated from peripheral blood monocytes of healthy donors and incubated with zoledronic acid (Zol) for 24 hours. Zol-treated iDC and mDC retained their immunostimulatory properties and induced the vigorous expansion of central memory and effector memory gammadelta T cells. gammadelta T cells displayed antitumor activity and appropriate cell surface antigens to target secondary lymphoid organs and exert costimulatory activity. Antigen-specific MHC-restricted immune responses, mediated by conventional alphabeta T cells, were improved by the concurrent gammadelta T-cell activation. In conclusion, large numbers of gammadelta T cells with effector and costimulatory activities are rapidly generated by Zol-treated iDC/mDC. This strategy is worthy of further investigation to improve adoptive cell therapy and vaccine interventions against tumors and infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403919     DOI: 10.1182/blood-2006-09-044321

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.

Authors:  Maria Raffaella Zocchi; Delfina Costa; Roberta Venè; Francesca Tosetti; Nicoletta Ferrari; Simona Minghelli; Roberto Benelli; Stefano Scabini; Emanuele Romairone; Silvia Catellani; Aldo Profumo; Alessandro Poggi
Journal:  Oncoimmunology       Date:  2017-01-06       Impact factor: 8.110

Review 2.  Use of tumour-responsive T cells as cancer treatment.

Authors:  Mary L Disis; Helga Bernhard; Elizabeth M Jaffee
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

Review 3.  Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.

Authors:  Barbara Castella; Candida Vitale; Marta Coscia; Massimo Massaia
Journal:  Cell Mol Life Sci       Date:  2011-05-17       Impact factor: 9.261

Review 4.  The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?

Authors:  Domenico Galati; Serena Zanotta; Marialuisa Bocchino; Rosaria De Filippi; Antonio Pinto
Journal:  Cancer Immunol Immunother       Date:  2021-01-01       Impact factor: 6.968

5.  Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells.

Authors:  Xiaosan Su; Lei Zhang; Liangkun Jin; Junsong Ye; Zheng Guan; Rui Chen
Journal:  J Clin Immunol       Date:  2010-06-15       Impact factor: 8.317

6.  Stress-related and homeostatic cytokines regulate Vγ9Vδ2 T-cell surveillance of mevalonate metabolism.

Authors:  Georg Gruenbacher; Oliver Nussbaumer; Hubert Gander; Bernhard Steiner; Nicolai Leonhartsberger; Martin Thurnher
Journal:  Oncoimmunology       Date:  2014-11-14       Impact factor: 8.110

7.  Technetium-99 conjugated with methylene diphosphonate ameliorates ovariectomy-induced osteoporotic phenotype without causing osteonecrosis in the jaw.

Authors:  Yinghua Zhao; Lei Wang; Yi Liu; Kentaro Akiyama; Chider Chen; Ikiru Atsuta; Tao Zhou; Xiaohong Duan; Yan Jin; Songtao Shi
Journal:  Calcif Tissue Int       Date:  2012-10-12       Impact factor: 4.333

8.  The evolving role of zoledronic acid in early breast cancer.

Authors:  Michael Gnant
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

Review 9.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

10.  Vdelta2 T-lymphocyte responses in cord blood samples from Italy and Côte d'Ivoire.

Authors:  Cristiana Cairo; Giorgio Mancino; Giulia Cappelli; C David Pauza; Elena Galli; Ercole Brunetti; Vittorio Colizzi
Journal:  Immunology       Date:  2008-01-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.